Alzheimer's Disease Forecast in 12 Major Markets 2017-2027 Split by Gender and 5-Year Age Cohort & Current Prevalence

Dublin, March 27, 2017 -- Research and Markets has announced the addition of the "Alzheimer's Disease Forecast in 12 Major Markets 2017-2027" report to their offering.

Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder. It is the leading cause of dementia. Alzheimer's is associated with the increase of beta amyloid and tau proteins in the brains of affected patients.

Cognitive function declines and patients suffer memory loss and disorientation amongst many other neuropsychiatric conditions as the disease progresses.

This report provides the current prevalent population for Alzheimer's disease across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Alzheimer's have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Alzheimer's disease include:

• Other dementias
• Depression and other psychiatric conditions
• Hypertension
• Diabetes
• Glaucoma
• Osteoporosis and osteopenia
• Education level / years of education

Reasons to Buy

• Able to quantify patient populations in global Alzheimer's disease's market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Alzheimer's disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Alzheimer's disease's prevalent population.
• Identify sub-populations within Alzheimer's disease which require treatment.
• Gain an understanding of the specific markets that have the largest number of Alzheimer's disease patients.

Key Topics Covered:

1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line prevalence for Alzheimer's disease
10. Features of Alzheimer's disease patients
11. Neuropsychiatric symptoms of AD patients
12. Comorbid Conditions of AD patients
13. Abbreviations used in the report
14. Patient-Based Offering
15. Online Pricing Data and Platforms
16. References
17. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/t4rjn7/alzheimers

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Alzheimer's Disease Drugs